Literature DB >> 22991013

The balANZ study--strengthening the evidence for neutral-pH solutions low in glucose degradation products.

Martin Wilkie1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22991013      PMCID： PMC3524862          DOI： 10.3747/pdi.2012.00204

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN： 0896-8608            Impact factor:   1.756


× No keyword cloud information.
  21 in total

1.  Glucose degradation products in peritoneal dialysis fluids: how they can be avoided.

Authors:  A Wieslander; T Linden; P Kjellstrand
Journal:  Perit Dial Int       Date:  2001       Impact factor: 1.756

2.  Grading quality of evidence and strength of recommendations.

Authors:  David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza
Journal:  BMJ       Date:  2004-06-19

Review 3.  A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance.

Authors:  Amit X Garg; Tom Greene; Nathan W Levin
Journal:  Nephrol Dial Transplant       Date:  2007-10-31       Impact factor: 5.992

4.  Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.

Authors:  Simon J Davies; Louise Phillips; Patrick F Naish; Gavin I Russell
Journal:  J Am Soc Nephrol       Date:  2001-05       Impact factor: 10.121

5.  Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription.

Authors:  Simon J Davies; Edwina A Brown; Niels E Frandsen; Anabela S Rodrigues; Ana Rodriguez-Carmona; Andreas Vychytil; Evelyne Macnamara; Agneta Ekstrand; Anders Tranaeus; Jose C Divino Filho
Journal:  Kidney Int       Date:  2005-04       Impact factor: 10.612

Review 6.  The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?

Authors:  Jeffrey Perl; Sharon J Nessim; Joanne M Bargman
Journal:  Kidney Int       Date:  2011-01-19       Impact factor: 10.612

Review 7.  Public involvement at the design stage of primary health research: a narrative review of case examples.

Authors:  Jonathan Boote; Wendy Baird; Claire Beecroft
Journal:  Health Policy       Date:  2009-12-05       Impact factor: 2.980

8.  Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients.

Authors:  Ramón Paniagua; María-de-Jesús Ventura; Marcela Avila-Díaz; Alejandra Cisneros; Marlén Vicenté-Martínez; María-Del-Carmen Furlong; Zuzel García-González; Diana Villanueva; Oscar Orihuela; María-Del-Carmen Prado-Uribe; Guadalupe Alcántara; Dante Amato
Journal:  Perit Dial Int       Date:  2009 Jul-Aug       Impact factor: 1.756

9.  Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial.

Authors:  Simon J Davies; Graham Woodrow; Kieron Donovan; Jörg Plum; Paul Williams; Ann Catherine Johansson; Hans-Peter Bosselmann; Olof Heimbürger; Ole Simonsen; Andrew Davenport; Anders Tranaeus; Jose C Divino Filho
Journal:  J Am Soc Nephrol       Date:  2003-09       Impact factor: 10.121

10.  The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Nephrol Dial Transplant       Date:  2012-08-01       Impact factor: 5.992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.